Lexitas Pharma Services Welcomes Dr. David Tanzer as Chief Medical Officer
DURHAM, NC (March 24, 2025) – Lexitas Pharma Services is proud to announce that David Tanzer, MD has joined the organization as Chief Medical Officer. With his extensive experience in ophthalmology and leadership in clinical research, Dr. Tanzer will further strengthen Lexitas’ medical and scientific expertise, reinforcing its position as a premier ophthalmic clinical research organization (CRO).
Dr. Tanzer has been a valued collaborator with Lexitas, both as a client sponsor and most recently serving as a consultant supporting both the operations and business development teams. A board-certified and fellowship-trained ophthalmologist, he brings over 20 years of broad-based leadership experience across clinical practice, private sector companies (OcuTerra Therapeutics, Johnson & Johnson Vision, Abbott Medical Optics, and Novartis), non-profits, academic institutions, and military organizations. His expertise spans research and development, medical affairs, safety, commercialization, compliance, and quality assurance within the healthcare sector. Dr. Tanzer has a proven track record of driving innovation, supporting commercial product growth, and leading global medical affairs teams, with deep experience in all phases of clinical research and trial management.
“Lexitas has built an outstanding reputation in ophthalmology research, and I am thrilled to join this talented team and contribute to advancing clinical research that ultimately improves patient outcomes,” said Dr. Tanzer. “I’ve seen firsthand their dedication to scientific excellence and innovation, and I look forward to helping drive continued success in this space.”
Jeanne Hecht, CEO of Lexitas, expressed her enthusiasm about Dr. Tanzer’s appointment: “David’s deep expertise in ophthalmology and his proven leadership in clinical research makes him an invaluable addition to our team. His strategic vision and commitment to scientific excellence will further strengthen our ability to support our customers and drive innovation in ophthalmic product development. We are powered by our vision to change the way people see the world.”
With Dr. Tanzer joining the executive team, Lexitas is poised to continue its growth and innovation in ophthalmic clinical trials, delivering unparalleled expertise and customized solutions for clients worldwide.
For more information about Lexitas and its leadership team, visit www.lexitas.com.
About Lexitas Pharma Services
Lexitas is a premier clinical research organization dedicated to advancing ophthalmology research through unmatched expertise, tailored approaches, and rigorous quality standards. Our team of experts, including ophthalmologists, optometrists, and clinical operations specialists, brings extensive medical, scientific, regulatory, and operational knowledge across all ophthalmology subspecialties. With a deep understanding of patient treatment pathways, provider and research networks, and market opportunities, Lexitas provides customized solutions that support your needs at every stage of development. Learn more about Lexitas at www.lexitas.com and follow us on LinkedIn.
Media Contacts
Shannon Severino
shannon@severinocommunications.com
412.608.2393